 |
|
||||||
| •treatment options |
TEXT SIZE
 
|
back
|
VORINOSTATVorinostat is an oral histone deacetylase inhibitor (HDACi) that alters gene expression and protein activity. It has shown promise in the treatment of multiple myeloma. |
print
|
|
|||
| Merck-sponsored Phase III multi-national study in patients with relapsed or refractory multiple myeloma. | |||
|
|||
| Merck-sponsored Phase IIb multi-national study in patients with relapsed or refractory multiple myeloma after at least 2 prior treatment regimens. | |||
back to top